NYSE · BDX
Becton, Dickinson and Company
$198.34+$3.18 (+1.63%)
Becton, Dickinson and Company’s quoted price sits in the upper half of its reported 52-week range, 1.06% below the high.
Loading market information…
NYSE · SOLV · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Solventum Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Solventum Corporation’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $1.34. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Solventum Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | $1.34+10.74% vs estimate | $2.07B+2.66% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $1.41+7.63% vs estimate | $2.07B+1.13% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $1.64+17.99% vs estimate | $2.08B+1.25% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $95.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$198.34+$3.18 (+1.63%)
Becton, Dickinson and Company’s quoted price sits in the upper half of its reported 52-week range, 1.06% below the high.
$23.50-$1.96 (-7.7%)
Baxter International Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.67% below the high.
$60.34+$0.93 (+1.57%)
The Cooper Companies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.83% below the high.
$86.44+$1.48 (+1.74%)
Henry Schein, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.23% below the high.
£2.43-£0.01 (-0.33%)
ConvaTec Group Plc’s quoted price sits in the upper half of its reported 52-week range, 6.21% below the high.
$93.39+$1.18 (+1.28%)
Merit Medical Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.66% below the high.
$168.65+$2.26 (+1.36%)
ICU Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.55% below the high.
$24.61+$0.67 (+2.8%)
Envista Holdings Corp’s quoted price sits in the upper half of its reported 52-week range, 19.1% below the high.
